Status:
COMPLETED
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
Lead Sponsor:
Repligen Corporation
Conditions:
Pancreatitis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of RG1068 (synthetic human secretin) with MRCP in subjects with abnormalities of the pancreas.
Eligibility Criteria
Inclusion
- History of pancreatitis
- Medically stable
- Able to give informed consent
Exclusion
- Prior history of pancreatic resection
- Prior history of pancreatic duct drainage procedure
- Presence of a pancreatic stent
- Unstable cardiovascular disease
- Any contraindication to MRI procedure
- Pregnancy
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
258 Patients enrolled
Trial Details
Trial ID
NCT00660335
Start Date
March 1 2008
End Date
October 1 2009
Last Update
December 3 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.